Meril Life Sciences has introduced MyClip, India’s first Transcatheter Edge-to-Edge Repair (TEER) system, on June 14. The launch event, held at Meril Academy in Vapi (Gujarat), gathered over 150 interventional cardiologists and cardiac imaging specialists from across India for the Structural Heart Innovation event.
Currently recognized as a global leader in TAVI (Transcatheter Aortic Valve Implantation) with its Myval THV platform, Meril becomes the first Indian company to launch a TEER system. This positions India prominently on the global map of transcatheter heart valve therapies, which include both replacement and repair technologies. The introduction of MyClip highlights India’s expanding capabilities in structural heart interventions and reflects Meril’s ongoing dedication to delivering cutting-edge and accessible cardiac care solutions.
The MyClip TEER System is particularly suited for patients with severe Mitral Regurgitation (MR) who are at elevated surgical risk due to conditions such as hypertension, diabetes, obesity, advanced age, frailty, enlarged or weakened hearts, and complications related to kidney, lung, or liver disease. Without timely intervention, MR can have a devastating prognosis—over 50% of untreated patients may not survive, with one-year mortality rates reaching as high as 57%.
MyClip offers precise closure of the mitral valve leaflets, effectively preventing the backward leakage of blood into the lungs. The minimally invasive procedure typically takes about one hour, allowing patients to return home within 3–5 days. After discharge, most patients can resume daily activities like walking and light work within a short recovery period.
The system’s clinical benefit is supported by data from the landmark COAPT trial, published in the New England Journal of Medicine (NEJM). In this study, patients undergoing device-based mitral repair showed substantially better outcomes than those receiving only standard medical therapy. Over 24 months, hospitalizations for heart failure decreased to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Mortality was also significantly lower: 29.1% in the device group versus 46.1% in the control group.
Currently, around 150 TEER procedures are performed annually in India, mostly in younger patients aged 30–60 years, highlighting an urgent need for early interventions in this demographic.
The introduction of MyClip marks a transformative milestone for structural heart care in India. TEER therapy has demonstrated clear advantages over conventional Guideline Directed Medical Therapy (GDMT) and signals a major advancement in India’s cardiovascular treatment landscape.
In his address, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, shared that approximately 1.5 million people in India are estimated to suffer from severe mitral regurgitation, with at least 1.2 million developing MR after myocardial infarction or heart failure. The launch of MyClip represents a pivotal shift towards early adoption of TEER therapy. Bhatt emphasized the importance of Meril’s initiatives in training cardiologists and advancing TEE-based imaging, which are key to expanding this life-saving technology nationwide.
Bhatt further stated:
"With MyClip, Meril is redefining India’s place in the global medtech arena. This indigenous innovation showcases the power of collaboration across Indian science, engineering, and clinical practice. Our national public awareness campaign, #TreatmentZarooriHai, fronted by brand ambassador MS Dhoni, is actively educating patients and families about the critical importance of timely intervention in mitral valve regurgitation."
The two-day Structural Heart Innovation conference featured live case demonstrations, interactive workshops, and lectures by leading interventional cardiologists and echocardiologists. The event concluded with a strong call to build a robust M-TEER ecosystem in India, focused on accessibility, clinical excellence, and ongoing innovation.